Elmiron Vision Damage Lawsuits: Retinal Injuries, Maculopathy, and Vision Loss Claims

Reviewed by Credible Law’s mass tort review team | Last updated: 2026

---

Tens of thousands of Americans have relied on Elmiron to manage the daily, often debilitating pain of interstitial cystitis. For nearly a quarter century, it stood as the only oral medication ever approved by the U.S. Food and Drug Administration for that condition. What patients were never told — until 2020, when the warning label was finally updated — was that long-term use of Elmiron has been linked to a unique form of retinal damage that can permanently impair vision.

If you took Elmiron for years and now struggle with blurred vision, distorted images, dark spots, or difficulty adjusting to low light, those symptoms may not be ordinary aging. They may be the signature pattern of pentosan polysulfate sodium maculopathy — a drug-induced retinal injury that researchers and ophthalmologists have spent the last several years documenting in peer-reviewed literature.

Credible Law represents patients nationwide who developed pigmentary maculopathy, retinal toxicity, or permanent vision loss after long-term Elmiron use. We review every case at no cost, advance all litigation expenses, and only collect a fee if compensation is recovered for you. For a broader look at our pharmaceutical injury practice, see our overview of product liability claims and mass tort lawsuits.

Free Case Review • Nationwide Representation • No Fees Unless Compensation Is Recovered

Call (XXX) XXX-XXXX | Start Your Free Case Review

---

What Is Elmiron?

Elmiron is the brand name for pentosan polysulfate sodium (PPS), a semi-synthetic compound derived from beechwood hemicellulose. The U.S. Food and Drug Administration approved it in 1996 for the treatment of interstitial cystitis — a chronic and frequently misunderstood bladder condition characterized by pelvic pain, urinary urgency, and discomfort that can last decades. Elmiron remains the only oral medication ever approved by the FDA for this condition, and that monopoly has shaped both its prescribing patterns and the long-term exposure profile that ultimately led to the litigation now pending in federal court.

The drug is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and is typically prescribed at 100 mg three times daily — a regimen many patients follow for years and, in a substantial number of documented cases, for more than a decade. Because interstitial cystitis is a chronic condition with no cure, prescriptions are rarely written with an exit strategy in mind. Thousands of patients have therefore accumulated cumulative Elmiron exposure well into the hundreds of thousands of milligrams over the course of treatment.

The mechanism by which Elmiron is believed to relieve interstitial cystitis symptoms involves restoring the protective glycosaminoglycan layer on the bladder wall, which is thought to be deficient or damaged in IC patients. While that mechanism is reasonably well understood, the way Elmiron affects the eye — and specifically the retinal pigment epithelium at the back of the macula — is the subject of ongoing research documented by the U.S. Food and Drug Administration and the American Academy of Ophthalmology. What is no longer in dispute is that long-term exposure can produce a recognizable, vision-threatening pattern of retinal injury that carries the patient’s prescription history as its fingerprint.

How Elmiron May Cause Vision Damage

The link between Elmiron and a distinctive form of retinal injury was first formally identified in 2018 by Dr. Nieraj Jain and his colleagues at the Emory Eye Center. While reviewing patients who had been classified as having pattern dystrophy — a category of inherited retinal diseases — Dr. Jain noticed that a subset shared an uncommon trait: they had all taken pentosan polysulfate sodium for many years, with a median exposure of roughly 16 years. The retinal findings, while subtle on routine fundus examination, became unmistakable under advanced multimodal imaging.

The proposed mechanism centers on the retinal pigment epithelium, or RPE — a critical layer of cells that supports the photoreceptors responsible for central vision. Researchers believe long-term exposure to pentosan polysulfate sodium leads to gradual injury of the RPE, producing the characteristic pigmentary changes that define this maculopathy. The damage tends to be cumulative and dose-dependent: the longer and higher the exposure, the greater the risk.

A 2020 study by Vora and colleagues at Kaiser Permanente, published in Ophthalmology, quantified that dose-response relationship in striking terms. Among patients who had taken cumulative doses of 500 to 999 grams of pentosan polysulfate sodium, roughly 11 percent showed definitive signs of maculopathy. Among those who had taken more than 1,500 grams, that figure climbed to 42 percent. Patients with maculopathy in that cohort had ingested an average of approximately 14,000 capsules of Elmiron, compared to about 10,500 capsules among those without retinal findings.

What sets Elmiron-related maculopathy apart from more common retinal diseases like age-related macular degeneration is its capacity for mimicry. The condition can be mistaken for AMD, pattern dystrophy, or several inherited retinal disorders, and patients are often initially misdiagnosed. It typically takes a retinal specialist familiar with the disease — and modern imaging modalities including optical coherence tomography (OCT), fundus autofluorescence (FAF), and near-infrared reflectance imaging — to confirm the pattern. Major retinal centers including the Cleveland Clinic and Mayo Clinic have incorporated PPS maculopathy into their differential diagnosis for atypical macular findings.

Symptoms of Elmiron Eye Damage

The symptoms of pentosan polysulfate sodium maculopathy can be subtle in the early stages and easy to attribute to ordinary aging or unrelated eye disease. Recognizing the pattern is critical, because earlier identification means earlier discontinuation of the drug — and potentially less progression. Patients with Elmiron-related retinal injury commonly report:

• Blurry or distorted central vision
• Difficulty reading or recognizing faces
• Trouble adjusting from bright environments to dim ones
• Prolonged dark adaptation, especially when entering theaters or driving at dusk
• Dark or pale spots in the field of vision (paracentral scotomas)
• Wavy or warped lines (metamorphopsia)
• Reduced contrast sensitivity
• Difficulty driving at night
• A general sense that vision has changed in a way that does not correspond to a routine refraction adjustment

One particularly important clinical feature, supported by published longitudinal studies, is that the disease can continue progressing even after the patient stops taking Elmiron. A 2020 study published in JAMA Ophthalmology by Shah and colleagues tracked patients after drug cessation and documented continued retinal changes in a substantial proportion. That progression underscores why timely diagnosis matters: stopping the drug does not necessarily stop the injury, but it does halt further drug-induced exposure to a tissue that has limited capacity to heal.

Patients who notice any of these symptoms — particularly those with a long history of Elmiron use — should request an evaluation with a retinal specialist familiar with PPS maculopathy and ask specifically about multimodal imaging. Many ophthalmologists will not test for this condition unless prompted.

What Is Pigmentary Maculopathy?

Pigmentary maculopathy is an umbrella term for diseases affecting the macula — the small, central portion of the retina responsible for the detailed vision used for reading, driving, and recognizing faces — that produce abnormal pigment changes visible on examination and imaging. In the context of Elmiron, the term refers specifically to a unique pattern of retinal injury linked to long-term exposure to pentosan polysulfate sodium.

What makes this maculopathy distinct from the better-known age-related macular degeneration is the appearance of the retina under specialized imaging. On fundus examination, ophthalmologists frequently observe hyperpigmented spots throughout the macula, often interspersed with pale yellow deposits. On optical coherence tomography (OCT), there are areas of retinal pigment epithelium elevation or thickening that correspond to bright reflectance on near-infrared imaging. On fundus autofluorescence (FAF), a hallmark finding is a symmetric, confluent pattern of bright (hyperautofluorescent) and dark (hypoautofluorescent) spots that nearly always involve the fovea — the center of the macula — and frequently extend toward the retinal periphery.

This imaging signature is so consistent that researchers have, in published case series, used it to identify previously undiagnosed Elmiron maculopathy in patients whose retinal findings had been attributed to other diseases for years. The diagnostic process typically involves:

• A dilated fundus examination by a retinal specialist
• Optical coherence tomography of the macula
• Fundus autofluorescence imaging
• Near-infrared reflectance imaging
• A careful medication history, with particular attention to cumulative pentosan polysulfate sodium exposure
• In some cases, electroretinography or genetic testing to rule out inherited retinal disease

Whether the disease is reversible is one of the most important — and most painful — questions for patients. Current evidence suggests that while progression may slow after stopping the drug, structural retinal damage that has already occurred is generally not reversible. Some patients report stable vision after discontinuation; others continue to experience deterioration. This permanence is one of the central facts driving the legal claims now pending against Janssen Pharmaceuticals.

Scientific Studies Linking Elmiron to Vision Loss

The body of peer-reviewed evidence connecting Elmiron to retinal injury has grown rapidly since the original Emory case series. Each major study has added a piece of the picture — first identifying the pattern, then characterizing it across multiple centers, then quantifying the population-level risk, and finally tracking the disease course over time.

2018 — Pearce, Chen, and Jain (Emory Eye Center)

Published in Ophthalmology, this retrospective case series of six adult patients with long-term pentosan polysulfate sodium exposure first described what is now recognized as PPS maculopathy. The median duration of drug use was approximately 16 years. The paper was named Best Original Paper at the 2018 American Academy of Ophthalmology meeting and effectively launched the field of inquiry. Available via the National Institutes of Health PubMed database.

2019 — Hanif et al. (Macula Society Multicenter Study)

Published in JAMA Ophthalmology, this multicenter case series expanded the dataset to 35 patients and 64 eyes across multiple institutions. The study cataloged the clinical and imaging features of the disease in detail, identifying the symmetric, confluent pattern of hyperpigmented and pale yellow lesions and confirming retinal pigment epithelium atrophy as a feature of more advanced disease.

2020 — Vora, Patel, and Melles (Kaiser Permanente)

Published in Ophthalmology, this study analyzed a large cohort of Kaiser Permanente patients and produced what remains the most-cited dose-response data in the litigation. The findings — 11 percent maculopathy prevalence at cumulative doses of 500 to 999 grams, rising to 42 percent at doses exceeding 1,500 grams — transformed the conversation from “is there an association” to “how serious is the dose relationship.”

2020 — Shah et al. (Disease Course After Cessation)

Published in JAMA Ophthalmology, this longitudinal study followed patients with PPS maculopathy after drug cessation and documented continued progression in a meaningful subset, supporting the conclusion that the structural damage may not stop simply because the medication does.

2020 — Jain et al. (US Claims Database Study)

Published in the British Journal of Ophthalmology, this retrospective matched cohort study used a large US medical claims database from 2002 to 2016 to evaluate the association at population scale. The study reported a statistically significant elevated odds ratio of 1.41 (95% CI 1.09–1.82) for atypical maculopathy among PPS users compared with matched controls — the kind of population-level signal that supports causation arguments in mass tort litigation.

2022 — Lindeke-Myers, Hanif, and Jain (Comprehensive Review)

Published in Survey of Ophthalmology, this comprehensive review article synthesized the literature on pentosan polysulfate maculopathy and effectively codified the clinical and imaging criteria now used to diagnose it.

2025 — Wake Forest Retrospective Series

A 2025 single-center retrospective series from Wake Forest School of Medicine reported an 11 percent prevalence rate of pigmentary maculopathy among PPS-exposed interstitial cystitis patients evaluated with multimodal imaging — a finding consistent with the broader literature.

The scientific consensus, while still evolving on mechanism, no longer disputes the basic association: long-term exposure to pentosan polysulfate sodium is associated with a distinctive, often progressive form of retinal injury.

FDA Warnings and Label Changes

Elmiron was approved by the FDA in 1996 with no warning regarding retinal toxicity. For nearly 24 years, the drug’s prescribing information contained no caution about possible eye injury, even as patients accumulated decades of exposure.

That changed in June 2020, when the FDA required Janssen Pharmaceuticals to update Elmiron’s label to include a new warning regarding changes in the retina of the eye, identified as pigmentary maculopathy. The updated label advised that patients with a family history of inherited eye diseases or patients with vision-related symptoms be evaluated. It also recommended that patients on long-term Elmiron therapy receive a baseline retinal examination shortly after initiating treatment and undergo periodic retinal evaluations thereafter.

The timing — more than two years after the original Emory study and more than two decades after FDA approval — is central to the lawsuits now pending against Janssen. Plaintiffs allege that Janssen knew or should have known of the risk much earlier, citing internal pharmacovigilance obligations, post-marketing surveillance requirements, and the company’s own monitoring of adverse event reports. The lawsuits do not claim Janssen invented Elmiron negligently; they claim that the company failed to warn doctors and patients in a timely manner once evidence of harm began to emerge.

The FDA has not, to date, issued a recall of Elmiron, and the drug remains on the market as the only oral FDA-approved treatment for interstitial cystitis. That regulatory posture reflects the practical reality that many IC patients have no comparable alternative — but it does not diminish the legal exposure for failures during the period before the warning was added. For an overview of how regulatory failures intersect with civil liability, see our discussion of toxic tort litigation.

Elmiron Lawsuit Allegations

The plaintiffs in the Elmiron mass tort have brought claims grounded in well-established product liability law. The central allegations include:

• Failure to warn. Plaintiffs allege Janssen Pharmaceuticals knew or should have known about the risk of pigmentary maculopathy and other forms of retinal toxicity before the 2020 label change, and that the company failed to provide adequate warnings to physicians and patients during the years that meaningful evidence was emerging.
• Negligent design and manufacturing. While the precise mechanism of injury continues to be studied, plaintiffs assert Janssen had a duty to investigate and address the potential ocular toxicity profile of pentosan polysulfate sodium, particularly given the long-term use pattern that the drug’s chronic indication required.
• Negligent post-marketing surveillance. Pharmaceutical manufacturers have ongoing obligations to monitor adverse events and update warnings as evidence accumulates. Plaintiffs allege Janssen’s pharmacovigilance was inadequate given the volume and quality of evidence available.
• Strict product liability. Under the strict liability doctrines applied in most jurisdictions, a product that is unreasonably dangerous due to inadequate warnings can subject the manufacturer to liability without requiring proof of negligence in the traditional sense.
• Breach of implied and express warranties. Allegations that Elmiron was not fit for the purpose for which it was sold given its undisclosed retinal toxicity risk.
• Fraudulent misrepresentation and concealment. Some complaints allege Janssen affirmatively misrepresented or concealed the safety profile of the drug.

These claims have been extensively pleaded and tested in motion practice over the course of the multidistrict litigation and remain the framework under which settlement negotiations have been proceeding. They mirror the legal theories used in other recent pharmaceutical mass torts, including the Taxotere hair loss litigation.

Who May Qualify for an Elmiron Lawsuit?

While every claim is evaluated on its individual facts, certain core criteria are common to nearly every viable Elmiron vision damage case. You may qualify for compensation if:

• You were prescribed and took Elmiron, typically for interstitial cystitis or chronic bladder pain
• Your use was generally long-term — most documented cases involve cumulative exposure of two years or more, with risk increasing significantly at longer durations
• You have a documented medical diagnosis of pigmentary maculopathy, retinal toxicity, retinal pigment epithelium damage, or another retinal injury consistent with PPS maculopathy
• The diagnosis was made or confirmed by a retinal specialist or ophthalmologist using appropriate imaging (OCT, FAF, near-infrared reflectance)
• You can produce pharmacy records, prescription records, or other documentation establishing your Elmiron exposure
• The statute of limitations applicable to your state has not expired (and in many states, the discovery rule may extend the filing window because patients were frequently misdiagnosed before the PPS link was identified)

A confirmed diagnosis is the cornerstone of a viable claim. If you have vision symptoms but have not yet been formally evaluated for PPS maculopathy, a retinal specialist consultation is the critical next step — both for your medical care and for any potential legal claim. Our team can help you understand what records to gather. To speak with our pharmaceutical mass tort team, contact Credible Law for a free, confidential review.

Do You Qualify? Get a Free Case Review →

How Much Is the Elmiron Lawsuit Worth?

Honest answers about Elmiron settlement values require care. Janssen Pharmaceuticals has been resolving cases through confidential settlements since 2023, and the specific dollar amounts have not been publicly disclosed. No bellwether trial has produced a jury verdict to anchor public valuation expectations, and any law firm offering specific settlement projections is, at this stage, speculating.

What we can say with confidence is that compensation in pharmaceutical product liability cases of this nature is typically structured around several categories of damages:

• Economic damages. Past and future medical expenses, including specialized retinal evaluations, imaging, low-vision rehabilitation, and assistive technology; lost wages during periods of disability; reduced earning capacity if vision impairment limits the ability to perform prior work; and out-of-pocket costs related to vision-impairment accommodations.
• Non-economic damages. Pain and suffering, loss of enjoyment of life, the emotional toll of permanent vision impairment, and the day-to-day impact of conditions like difficulty reading, driving, or recognizing faces.
• Future care costs. Given the often progressive nature of pigmentary maculopathy, anticipated future medical and supportive care is a significant component of any responsible damages assessment.

In many mass tort settlements of this type, compensation is ultimately structured in tiers based on the severity of injury — for example, with substantially higher compensation for plaintiffs with severe central vision loss or legal blindness compared to those with milder structural changes and preserved acuity. Whether the Elmiron MDL will follow that tiered model in a global resolution remains to be seen. Compensation may vary depending on the severity of injury, duration of Elmiron use, documentation quality, and applicable state law.

Our role at Credible Law is to develop the strongest possible factual and medical record for each individual client so that, when a recovery is reached, it reflects the full impact of the injury on that person’s life.

Elmiron MDL and Current Litigation Updates

Most federal Elmiron lawsuits have been consolidated into multidistrict litigation MDL 2973, formally captioned In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, pending in the U.S. District Court for the District of New Jersey. The MDL was created by the Judicial Panel on Multidistrict Litigation in December 2020, shortly after the FDA-mandated label change. The litigation is presided over by U.S. District Judge Brian R. Martinotti, with Special Master Mark Falk facilitating discovery and settlement processes.

Key Litigation Milestones

• 2018 — First peer-reviewed evidence of PPS maculopathy published by the Emory team.
• June 2020 — FDA requires Janssen to update the Elmiron label with a retinal pigmentary changes warning.
• December 2020 — JPML creates MDL 2973 in the District of New Jersey.
• 2021–2022 — Discovery, Science Day proceedings, and bellwether case selection.
• February 2022 — Parallel state court multicounty litigation (MCL) created in Bergen County, New Jersey.
• September 2022 — Pennsylvania creates a state-level mass tort program for Elmiron cases.
• March 2023 — First scheduled bellwether trial (Maria Windham v. Janssen Pharmaceuticals) postponed; confidential settlements begin.
• August 2023 — Court establishes the Elmiron Fee Fund and Expense Fund as qualified settlement funds, signaling a structural commitment to global resolution.
• 2024–2026 — Confidential settlements continue; bellwether trials remain suspended; pending case count steadily declines as cases resolve.

Current Case Count

According to the most recent JPML statistics report, 634 Elmiron cases remained pending in MDL 2973 as of March 2026, out of nearly 2,000 total cases filed since the MDL’s inception. The substantial decline from peak case counts of approximately 1,900 reflects the volume of confidential settlements that have been quietly resolving claims since 2023.

The Pennsylvania state mass tort program is largely resolved, with most of its roughly 150 cases settled through confidential agreements. Bellwether trial dates in the federal MDL have been canceled and have not been rescheduled, with the parties continuing to pursue resolution rather than trial.

For patients still considering whether to file, time is now a real factor. While some firms continue to accept new Elmiron cases, the litigation is in its later stages, and statute of limitations issues become increasingly important the further out from initial diagnosis a patient files. To review where your potential claim stands, see our active mass tort cases page or contact our office directly.

What To Do If You Believe Elmiron Damaged Your Vision

If you have a history of long-term Elmiron use and have noticed changes in your vision — or if you have already been told you have macular degeneration, pattern dystrophy, or atypical retinal findings — the steps you take in the coming weeks will matter both medically and legally.

• 1. Schedule a retinal specialist evaluation. Ask specifically about pentosan polysulfate sodium maculopathy and request multimodal imaging including OCT, fundus autofluorescence, and near-infrared reflectance imaging.
• 2. Preserve your records. Gather pharmacy printouts, insurance claim records, and any prescriptions you can locate. Many pharmacies will produce records going back several years on request.
• 3. Document your prescriber history. Note when Elmiron was first prescribed, by whom, and for how long you took it. If you stopped, note when and why.
• 4. Avoid signing anything before legal review. Some patients have been approached by representatives offering quick settlements. Do not sign releases, settlement offers, or arbitration agreements without first having an experienced mass tort attorney review them.
• 5. Talk to a lawyer promptly. Statute of limitations rules vary by state, and even where the discovery rule applies, the analysis is fact-specific. With the MDL in its later stages, delay can foreclose otherwise viable claims.

Credible Law evaluates Elmiron cases at no cost. If we accept your case, we advance all litigation expenses, and you owe nothing unless and until we recover compensation for you. For more on our practice in pharmaceutical and medical injury claims, see our pages on personal injury and medical malpractice.

---

Frequently Asked Questions

Can Elmiron cause blindness?

Long-term Elmiron use has been linked to pigmentary maculopathy, which in advanced cases can cause severe central vision impairment. While most reported cases do not result in total blindness in the colloquial sense, severe cases can produce legal blindness through profound loss of central vision and reduced visual acuity. Whether a particular patient will progress to severe vision impairment depends on cumulative dose, duration of exposure, individual susceptibility, and how quickly the drug is discontinued after diagnosis.

Is Elmiron eye damage permanent?

Current evidence suggests that the structural retinal damage caused by long-term pentosan polysulfate sodium exposure is generally not reversible. Stopping the drug may slow or halt further injury, but a published longitudinal study found that progression can continue in some patients even after discontinuation. This is one of the central facts in the litigation.

What is pigmentary maculopathy?

Pigmentary maculopathy refers to a category of retinal diseases that produce abnormal pigment changes in the macula — the central portion of the retina responsible for sharp, detailed vision. In the Elmiron context, the term refers specifically to a unique pattern of injury linked to pentosan polysulfate sodium, with characteristic findings on optical coherence tomography, fundus autofluorescence, and near-infrared reflectance imaging.

How do I know if Elmiron damaged my eyes?

Common warning signs include blurred or distorted central vision, prolonged dark adaptation, difficulty reading, paracentral blind spots, and trouble driving at night. A retinal specialist using multimodal imaging is the only person qualified to confirm pentosan polysulfate sodium maculopathy. If you have a history of long-term Elmiron use, request specifically that your eye doctor evaluate for PPS maculopathy.

Is there an Elmiron class action lawsuit?

The Elmiron litigation is not a class action in the strict legal sense. It is multidistrict litigation (MDL 2973), which means individual cases are consolidated for pretrial efficiency but each plaintiff retains an individual claim and any recovery is tailored to that plaintiff’s injuries. Many people use the term class action colloquially to refer to mass torts, but the legal mechanics are different.

How much is the Elmiron lawsuit worth?

There are no publicly disclosed settlement amounts in MDL 2973. Janssen Pharmaceuticals has been resolving cases through confidential settlements since 2023, and no bellwether jury verdict exists to provide a public benchmark. Compensation in cases of this kind typically reflects medical costs, lost wages, future care, and pain and suffering, often structured in tiers based on injury severity. Anyone offering specific dollar projections at this stage is speculating.

How long do I have to file an Elmiron lawsuit?

The statute of limitations varies by state, typically running from two to four years from the date of diagnosis or from the date the patient reasonably should have known of the connection between Elmiron use and vision injury. Because many patients were misdiagnosed with age-related macular degeneration or pattern dystrophy before the PPS link was identified, the discovery rule may extend filing windows in many states. Given that the MDL is in its later stages, prompt action is critical.

What are the symptoms of Elmiron retinal toxicity?

Reported symptoms include blurred vision, distorted images (metamorphopsia), difficulty adjusting to changes in light, prolonged dark adaptation, dark or pale spots in the central field of vision, reduced reading ability, and difficulty driving at night.

Can vision get worse after stopping Elmiron?

Yes. A 2020 longitudinal study published in JAMA Ophthalmology documented continued retinal changes in a meaningful subset of patients after drug cessation. This is one reason the disease is described as potentially progressive even when exposure ends.

What tests diagnose Elmiron eye damage?

Diagnosis typically involves a dilated fundus examination, optical coherence tomography (OCT) of the macula, fundus autofluorescence (FAF) imaging, and near-infrared reflectance imaging. Some patients also undergo electroretinography or genetic testing to rule out inherited retinal disorders that can mimic PPS maculopathy.

What is MDL 2973?

MDL 2973 is the federal multidistrict litigation captioned In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, pending in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti. It consolidates federal Elmiron vision damage cases for coordinated discovery and pretrial proceedings.

Is Elmiron still on the market?

Yes. The FDA has not recalled Elmiron, which remains the only oral FDA-approved treatment for interstitial cystitis. The June 2020 label update added a warning regarding retinal pigmentary changes, but the drug continues to be prescribed.

Has Janssen Pharmaceuticals settled any Elmiron lawsuits?

Yes — confidentially. Public reporting and court filings indicate Janssen has been resolving cases through confidential individual and group settlements since 2023, and the pending case count in MDL 2973 has declined substantially as a result. The specific terms of those settlements have not been publicly disclosed.

Do I have to pay anything to file an Elmiron claim with Credible Law?

No. We evaluate every potential case at no cost, advance all litigation expenses, and only collect a fee if compensation is recovered for you. There is no out-of-pocket risk to having your case reviewed.

---

Free, Confidential Case Review — Nationwide Representation

Call (XXX) XXX-XXXX | Start Your Case Review Online

---

Reviewed by Credible Law’s mass tort review team. Last updated: 2026.

Authoritative medical references: U.S. Food and Drug Administration; American Academy of Ophthalmology; National Institutes of Health PubMed; Mayo Clinic; Cleveland Clinic; peer-reviewed publications in Ophthalmology, JAMA Ophthalmology, British Journal of Ophthalmology, and Survey of Ophthalmology.

DISCLAIMER: This article is for general informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship with Credible Law. Past results do not guarantee future outcomes. Every case is different, and the value or success of any claim depends on the specific facts and applicable law. If you believe you may have an Elmiron-related vision injury claim, contact a qualified mass tort attorney promptly to discuss your individual situation.